IL17A and enthesitis: These adjuvants may activate entheseal stromal and immune resident cell populations leading to the activation of the IL-23/IL-17 axis, secretion of pro-inflammatory cytokines resulting in enthesitis, osteitis and joint local inflammation (40, 41).